Frazier Management LLC Autolus Therapeutics PLC Transaction History

Frazier Management LLC

  • $0
  • Q3 2022

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022
SELL
$3.52 - $5.46 $13.2 Million - $20.5 Million
-3,746,857 Closed
0 $0
Q4 2021

Feb 08, 2022
BUY
$5.1 - $7.0 $1.1 Million - $1.51 Million
216,200 Added 6.12%
3,746,857 $19.4 Million
Q3 2021

Nov 12, 2021
BUY
$5.32 - $7.37 $6.63 Million - $9.19 Million
1,246,691 Added 54.58%
3,530,657 $23.1 Million
Q2 2021

Aug 11, 2021
BUY
$4.78 - $7.96 $10.9 Million - $18.2 Million
2,283,966 New
2,283,966 $15.2 Million

Others Institutions Holding AUTL

# of Institutions
104
Shares Held
163M
Call Options Held
2.8K
Put Options Held
13.4K
View Full List

About Autolus Therapeutics plc

AUTL Quotes by TradingView
  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $272M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Frazier Management LLC Portfolio

Follow Frazier Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frazier Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email